Impact of Sanctions on Cancer Care in Iran

Document Type : EDITORIAL

Author

Mashhad University of Medical Sciences

Abstract

The right to health accepted as an essential human right.The US administration’s withdrawal from the Iran nuclear deal on May 2018, increased attention to the impact of sanctions on the health of more than 80 million Iranians. Sanctions will damage the Iran public health-care system, notably patients suffered from cancer. Cancers are the third cause of death in Iran. Diagnosis of malignancy is based on precise imaging studies and correct pathological results. To make a definite pathologic diagnosis, usually it is mandatory to add Immunohistochemical finding and genomic study with Histological finding . Furthermore, recent studies insist on the role of new imaging technology like whole body MRI in earlier detection of tumor spreading through the body. Economic sanctions target the government general budget and decrease Iran currency value, so the cost of these diagnosis methods will increase too much that the public health insurance wouldn’t afford them. Iran Radiotherapy facilities are less than world standard level. During the embargo before 2015, the amount of these facilities had fallen sharply. New chemotherapy drugs and new biologic anti-cancer agents are too expensive for the Iran public insurance system. Meticulous Surgery in cancers is related to the high-tech equipment’s. Difficulties in holding license for export of medical apparatus, financial transaction, and shipping insurance as well as fear of possible U.S. ban on international medical companies and international banks restrict the pathway of buying equipment needed for these surgeries. Moreover, Sanctions will endanger the cancer research in this country.

Keywords

Main Subjects


1. Hunt P. Interpreting the international right to health
in a human rights-based approach to health. Health
Hum Rights. 2016; 18(2):109-30.
2. Khangah HA, Jannati A, Imani A, Salimlar S,
Derakhshani N, Raef B. Comparing the health care
system of Iran with various countries. Health Scope.
2017; 6(1):e34459.
3. Shahabi S. International sanctions: Sanctions in Iran
disrupt cancer care. Nature. 2015; 520(7546):157.
4. Rouhollahi MR, Mohagheghi MA, Mohammadrezai
N, Ghiasvand R, Ghanbari Motlagh A, Harirchi I, et
al. Situation analysis of the national comprehensive
cancer control program in the I. R. of Iran; assessment
and recommendations based on the IAEA imPACT
Mission. Arch Iran Med. 2014; 17(4):222-31.
5. Schiffman JD, Fisher PG, Gibbs P. Early detection of
cancer: past, present, and future. Am Soc Clin Oncol
Educ Book. 2015; 35(1):57-65.
6. Yoshida A, Tsuta K, Ohno M, Yoshida M, Yoshitaka
N, Kawai A, et al. STAT6 immunohistochemistry is
helpful in the diagnosis of solitary fibrous tumors.
Am J Surg Pathol. 2014; 38(4):552-9.
7. Dancsok AR, Asleh-Aburaya K, Nielsen TO. Advances
in sarcoma diagnostics and treatment. Oncotarget.
2017; 8(4):7068-93.
8. Gorelik N, Reddy SMV, Turcotte RE, Goulding K, Jung
S, Alcindor T, et al. Early detection of metastases
using whole-body MRI for initial staging and routine
follow-up of myxoid liposarcoma. Skeletal Radiol.
2018; 47(3):369-79.
9. Barr RD, Wunder JS. Bone and soft tissue sarcomas
are often curable--but at what cost? a call to arms
(and legs). Cancer. 2009; 115(18):4046-54.
10. Ameri A, Barzegartahamtan M, Ghavamnasiri M,
Mohammadpour R, Dehghan H, Sebzari A, et al. Current
and future challenges of radiation oncology in Iran: a
report from the Iranian society of clinical oncology.
Clin Oncol (R Coll Radiol). 2018; 30(4):262-8.
11. Arab-zozani M. Health sector evolution in Iran; a
short review. Evid Based Health Policy Manag Econ.
2017; 1(3):193-7.
12. Mohammadi D. US-led economic sanctions strangle
Iran’s drug supply. Lancet. 2013; 381(9863):279.
13. Wong KC, Kumta SM. Joint-preserving tumor
resection and reconstruction using image-guided
computer navigation. Clin Orthop Relat Res. 2013;
471(3):762-73.
14. Mezger U, Jendrewski C, Bartels M. Navigation in
surgery. Langenbecks Arch Surg. 2013; 398(4):501-14.
15. Li Y, Branemark R. Osseointegrated prostheses for
rehabilitation following amputation: the pioneering
Swedish model. Unfallchirurg. 2017; 120(4):285-92.
16. Gorji A. Sanctions against Iran: the impact on health
services. Iran J Public Health. 2014; 43(3):381-2.
17. Al-Hadad SA, Al-Jadiry MF, Al-Darraji AF, Al-Saeed
RM, Al-Badr SF, Ghali HH. Reality of pediatric cancer
in Iraq. J Pediatr Hematol Oncol. 2011; 33(Suppl
2):S154-6.
18. Sen K, Al-Faisal W, AlSaleh Y. Syria: effects of conflict
and sanctions on public health. J Public Health. 2013;
35(2):195-9.
19. Garfield R. The public health impact of sanctions:
contrasting responses of Iraq and Cuba. Middle East
Report. 2000; 215(1):16-9.
20. Afshari R, Bhopal RS. Iran, sanctions, and research
collaborations. Lancet. 2016; 387(10023):1055-6.